Should I buy or sell Synlogic stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SYBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYBX, but not buy additional shares or sell existing shares. View SYBX analyst ratings or view top-rated stocks .

What is Synlogic's stock price target for 2024?

5 analysts have issued 1-year target prices for Synlogic's stock. Their SYBX share price targets range from $30.00 to $90.00. On average, they predict the company's share price to reach $65.00 in the next year. This suggests a possible upside of 3,375.9% from the stock's current price. View analysts price targets for SYBX or view top-rated stocks among Wall Street analysts .

How have SYBX shares performed in 2024?

Synlogic's stock was trading at $3.85 at the start of the year. Since then, SYBX stock has decreased by 51.4% and is now trading at $1.87. View the best growth stocks for 2024 here .

Are investors shorting Synlogic?

Synlogic saw a increase in short interest in March. As of March 31st, there was short interest totaling 38,600 shares, an increase of 70.8% from the March 15th total of 22,600 shares. Based on an average daily volume of 130,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.6% of the company's shares are sold short. View Synlogic's Short Interest .

When is Synlogic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SYBX earnings forecast .

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings data on Tuesday, March, 19th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($1.11) by $0.60. The biotechnology company had revenue of $2.77 million for the quarter, compared to analyst estimates of $2.71 million. Synlogic had a negative trailing twelve-month return on equity of 109.34% and a negative net margin of 1,699.23%.

When did Synlogic's stock split?

Shares of Synlogic reverse split before market open on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA) , Approach Resources (AREX) , Precision Drilling (PDS) , First Financial Bankshares (FFIN) , Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , Corbus Pharmaceuticals (CRBP) , Inovio Pharmaceuticals (INO) , Rigel Pharmaceuticals (RIGL) and Verastem (VSTM) .

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SYBX

Synlogic (SYBX) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free SYBX Stock Alerts

$1.89

+0.06 (+3.28%)

(As of 02:59 PM ET)

Compare

Today's Range: $1.78
▼
$1.89
50-Day Range: $1.72
▼
$1.97
52-Week Range: $1.55
▼
$10.20

Volume: 52,485 shs
Average Volume: 118,742 shs
Market Capitalization: $22.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $65.00

Get Synlogic alerts:

Synlogic MarketRank™ Stock Analysis

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 3,375.9% Upside
$65.00 Price Target
Short Interest: Healthy
0.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$969 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.09) to ($3.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

700th out of 918 stocks

Biotechnology Industry

18th out of 31 stocks

3.1

Analyst's Opinion

Consensus Rating
Synlogic has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Synlogic has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.63% of the float of Synlogic has been sold short.
Short Interest Ratio / Days to Cover
Synlogic has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Synlogic has recently increased by 70.80%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Synlogic does not currently pay a dividend.
Dividend Growth
Synlogic does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SYBX.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Synlogic this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added Synlogic to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Synlogic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $969.00 in company stock.
Percentage Held by Insiders
Only 8.01% of the stock of Synlogic is held by insiders.
Percentage Held by Institutions
63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Synlogic are expected to decrease in the coming year, from ($2.09) to ($3.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Synlogic is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Synlogic is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Synlogic has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Synlogic Stock (NASDAQ:SYBX)

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

SYBX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SYBX Stock News Headlines

April 16, 2024 | finance.yahoo.com

Synlogic, Inc. (SYBX)

April 6, 2024 | investing.com

Synlogic's head of finance sells shares worth $325

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

March 21, 2024 | markets.businessinsider.com

Hold Rating on Synlogic Amidst Lead Program Discontinuation and Strategic Uncertainties

March 19, 2024 | globenewswire.com

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

February 20, 2024 | finance.yahoo.com

Synlogic Adopts Limited Duration Stockholders Rights Plan

February 20, 2024 | globenewswire.com

Synlogic Adopts Limited Duration Stockholders Rights Plan

February 13, 2024 | markets.businessinsider.com

Hold Rating on Synlogic Amid Discontinued Lead Program and Reduced Price Target

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

February 9, 2024 | finanznachrichten.de

Synlogic, Inc.: Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

February 9, 2024 | in.investing.com

Synlogic plunges as it ceases operations following decision to discontinue Synpheny-3 study

February 9, 2024 | realmoney.thestreet.com

Synlogic just downgraded at Chardan, here's why

February 9, 2024 | msn.com

Rare Disease Focused-Synlogic Pulls Plug On Lead Program, Shares Nosedive

February 9, 2024 | bizjournals.com

Synlogic cuts most workers after halting rare disease drug trial

February 9, 2024 | msn.com

Synlogic shares crater amid company shut down, failed drug study

February 9, 2024 | msn.com

Why Is Synlogic (SYBX) Stock Down 55% Today?

February 9, 2024 | investorplace.com

Why Is Synlogic (SYBX) Stock Down 55% Today?

February 8, 2024 | marketwatch.com

Synlogic to Cease Operations, Cut Almost All Employees After Ending Trial

February 8, 2024 | marketwatch.com

Synlogic Shares Tumble 55% on Discontinued Trial, Halt to Operations

February 8, 2024 | msn.com

Synlogic to discontinue lead drug program, cease operations

February 8, 2024 | finance.yahoo.com

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

February 8, 2024 | finance.yahoo.com

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

February 6, 2024 | ca.finance.yahoo.com

Synlogic Inc (MIN.MU)

February 3, 2024 | finanznachrichten.de

Synlogic, Inc.: Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

February 2, 2024 | finance.yahoo.com

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

January 17, 2024 | benzinga.com

Synlogic Stock (NASDAQ:SYBX) Dividends: History, Yield and Dates

January 9, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), Enanta Pharmaceuticals (ENTA) and Synlogic (SYBX)

See More Headlines

Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SYBX
CUSIP: N/A
CIK: 1527599
Web: www.synlogictx.com
Phone: (617) 401-9975
Fax: 512-681-5201
Employees: 6
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $65.00
High Stock Price Target: $90.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +3,394.6%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($10.8767)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-57,280,000.00
Net Margins: -1,699.23%
Pretax Margin: -1,698.84%
Return on Equity: -109.34%
Return on Assets: -72.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.45
Quick Ratio: 2.45

Sales & Book Value

Annual Sales: $3.37 million
Price / Sales: 6.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.64 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 11,650,000
Free Float: 10,714,000
Market Cap: $21.67 million
Optionable: Optionable
Beta: 1.09

Social Links

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Antoine Awad (Age 43)
Principal Executive Officer & COO
Comp: $566.55k
Dr. Timothy K. Lu M.D. (Age 43)
Ph.D., Co-Founder & Member of Scientific Advisory Board
Dr. James J. Collins Ph.D. (Age 57)
Co-Founder & Member of Scientific Advisory Board
Ms. Mary Beth Dooley (Age 43)
Head of Finance and Principal Financial Officer & Principal Accounting Officer
Mr. Brendan St. Amant
General Counsel & Corporate Secretary
Mr. Ajay Munshi
Vice President of Corporate Development
Mr. Adam J. Thomas
Chief People Officer
Dr. Caroline B. Kurtz Ph.D.
Chief Development Officer
Ms. Molly Harper (Age 47)
Chief Business Officer
Dr. Neal Sondheimer M.D.
Ph.D., VP & Head of Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SYBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Synlogic stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SYBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYBX, but not buy additional shares or sell existing shares.
View SYBX analyst ratings or view top-rated stocks.
What is Synlogic's stock price target for 2024?: 5 analysts have issued 1-year target prices for Synlogic's stock. Their SYBX share price targets range from $30.00 to $90.00. On average, they predict the company's share price to reach $65.00 in the next year. This suggests a possible upside of 3,375.9% from the stock's current price.
View analysts price targets for SYBX or view top-rated stocks among Wall Street analysts.
How have SYBX shares performed in 2024?: Synlogic's stock was trading at $3.85 at the start of the year. Since then, SYBX stock has decreased by 51.4% and is now trading at $1.87.
View the best growth stocks for 2024 here.
Are investors shorting Synlogic?: Synlogic saw a increase in short interest in March. As of March 31st, there was short interest totaling 38,600 shares, an increase of 70.8% from the March 15th total of 22,600 shares. Based on an average daily volume of 130,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.6% of the company's shares are sold short.
View Synlogic's Short Interest.
When is Synlogic's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SYBX earnings forecast.

How were Synlogic's earnings last quarter?: Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings data on Tuesday, March, 19th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($1.11) by $0.60. The biotechnology company had revenue of $2.77 million for the quarter, compared to analyst estimates of $2.71 million. Synlogic had a negative trailing twelve-month return on equity of 109.34% and a negative net margin of 1,699.23%.
When did Synlogic's stock split?: Shares of Synlogic reverse split before market open on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Synlogic own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).
How do I buy shares of Synlogic?: Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYBX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Synlogic (SYBX) Stock Price, News & Analysis

Synlogic MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Synlogic Stock (NASDAQ:SYBX)

SYBX Stock Price History

SYBX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

SYBX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™